NCT05066672View on ClinicalTrials.gov

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

February 15, 2025

Study Completion Date

February 15, 2025

Conditions
Treatment Resistant Depression
Interventions
DRUG

NV-5138

NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling

DRUG

matched placebo

matched placebo oral capsules

Trial Locations (1)

98007

Northwest Clinical Research Center, Inc., Bellevue

Sponsors
All Listed Sponsors
collaborator

Supernus Pharmaceuticals, Inc.

INDUSTRY

lead

Navitor Pharmaceuticals, Inc.

INDUSTRY